We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TECX:NASDAQTectonic Therapeutic, Inc. Analysis

Data as of 2026-09-01 - not real-time

$29.94

Latest Price

8/10Risk

Risk Level: High

Executive Summary

The moving-average structure behind Tectonic Therapeutic, Inc. is bullish at $29.94, with short-term averages leading the long-term ones. The last 30 days have lost 6.6%. Momentum indicators put RSI at 40.3 (neutral) with MACD reading bearish. Recent trading has carved out support near $27.81 and resistance around $38.85.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 159.0% above the current price.
On a 1-10 scale the risk profile lands at 8 — high. With 30-day volatility of 87.1%, a beta of 1.04 and a maximum drawdown of 26.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.

Top Market Events

Benzinga.com25dTectonic Therapeutic Earnings & ForecastsTectonic Therapeutic NASDAQ:TECX reported quarterly losses of $...APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension...Nasdaq25dTectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business HighlightsWATERTOWN,...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 27.11
  • MACD momentum is negative

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 27.11
  • Analyst targets imply +159.0% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • Analyst targets imply +159.0% versus the current price
  • Negative return on equity of -33.8%
  • Negative free cash flow

Key Metrics & Analysis

Financial Health

P/E Ratio-6.4
ROE-33.80%
ROA-22.29%
Debt/Equity1.97
P/B Ratio2.4
Op. Cash Flow$-72140000
Free Cash Flow$-46723124
Industry P/E30.4

Technical Analysis

TrendBullish
RSI40.3
Support$27.81
Resistance$38.85
MA 20$34.19
MA 50$33.00
MA 200$27.11
MACDBearish
VolumeIncreasing
Fear & Greed Index93.38

Valuation

Target Price$77.56
Upside/Downside159.04%
GradeFair
TypeBlend

Risk Assessment

Beta1.04
Volatility87.07%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.